ANXA10 and neoplasm: Wallace et al. [33] and Pichler et al. [32] tested the Xpert BC Monitor®, a commercial kit that measures five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10), in a population of 510 patients and obtained sensitivities between 73 and 84% (100% in high-grade tumours) and a negative predictive value of 92–93%.